We are live on ! Find out more
KTOVW

Kitov Pharma Ltd. Warrants

Delisted

KTOVW was delisted on the 23rd of November, 2020.

3 hedge funds and large institutions have $8K invested in Kitov Pharma Ltd. Warrants in 2019 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

25% less funds holding

Funds holding: 43 (-1)

78% less capital invested

Capital invested by funds: $36K → $8K (-$28K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.06%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
2
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$5K -$885 -13,786 -15%
CAI
2
Capital Advisors Inc
Oklahoma
$3K
UBS Group
3
UBS Group
Switzerland
-$3 -40 -1%

KTOVW Hedge Fund Activity: Q4 2019 in Review

3 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Kitov Pharma Ltd. Warrants (KTOVW) for Q4 2019, worth a combined $8K — down 78% from $36K a quarter earlier.

Fund positioning in KTOVW was balanced in Q4 2019: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was Susquehanna International Group, cutting an estimated $885.

  • 3 institutional investors held Kitov Pharma Ltd. Warrants (KTOVW) as of Q4 2019, down from 4 in Q3 2019.
  • Funds reported $8K of Kitov Pharma Ltd. Warrants stock for Q4 2019, down 78% quarter-over-quarter.
  • 0 funds opened new Kitov Pharma Ltd. Warrants positions in Q4 2019 and 0 closed out.
  • The largest Kitov Pharma Ltd. Warrants seller in Q4 2019 was Susquehanna International Group, an estimated $885 sold.

Based on aggregated 13F filings for Q4 2019.